Project Details
| Status | Active |
|---|---|
| Effective start/end date | 29/09/23 → 28/08/26 |
Funding
- PAREXEL International Pty. Ltd.: A$75,000.00
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeruginosa Lung Infection
- Mulrennan, Siobhain (Investigator 01)